Published 2024 | Version v1
Journal article

First-in-human evaluation of 6-bromo-7-[11C]methylpurine, a PET tracer for assessing the function of multidrug resistance-associated proteins in different tissues

  • 1. Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna (Austria)
  • 2. Department of Clinical Pharmacology, Medical University of Vienna, Vienna (Austria)
  • 3. QIMP Team, Center for Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna (Austria)
  • 4. School of Neurobiology, Biochemistry and Biophysics, The Georg S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv (Israel)
  • 5. Department of Pharmacology, Faculty of Medicine and Life Sciences, University of Latvia, Rīga (Latvia)
  • 6. Institute of Nutritional Medicine (INUM) and Lübeck Institute of Dermatology (LIED), University of Lübeck and University Medical Center Schleswig-Holstein, Lübeck (Germany)
  • 7. Section of Neuropathology Research, Department of Pathology, Clinics for Laboratory Medicine (KLM), Oslo University Hospital, Oslo (Norway)
  • 8. Translational Neurodegeneration Research and Neuropathology Lab, Department of Clinical Medicine (KlinMed), Medical Faculty, University of Oslo, Oslo (Norway)

Description

Multidrug resistance-associated protein 1 (MRP1) is a transport protein with a widespread tissue distribution, which has been implicated in the pathophysiology of Alzheimer's and chronic respiratory disease. PET with 6-bromo-7-[11C]methylpurine ([11C]BMP) has been used to measure MRP1 function in rodents. In this study, [11C]BMP was for the first time characterised in humans to assess the function of MRP1 and other MRP subtypes in different tissues. Thirteen healthy volunteers (7 men, 6 women) underwent dynamic whole-body PET scans on a long axial field-of-view (LAFOV) PET/CT system after intravenous injection of [11C]BMP. Three subjects of each sex were scanned a second time to assess reproducibility. Volumes of interest were outlined for MRP-expressing tissues (cerebral cortex, cerebellum, choroid plexus, retina, lungs, myocardium, kidneys, and liver). From the time-activity curves, the elimination rate constant (kE, h1) was derived as a parameter for tissue MRP function and its test-retest variability (TRTV, %) was calculated. Radiation dosimetry was calculated using the Medical Internal Radiation Dose (MIRD) methodology. Mean kE and corresponding TRTV values were: cerebral cortex: 0.055 ± 0.010 h1 (-4 ± 24%), cerebellum: 0.033 ± 0.009 h1 (1 ± 39%), choroid plexus: 0.292 ± 0.059 h1 (0.1 ± 16%), retina: 0.234 ± 0.045 h1 (30 ± 38%), lungs: 0.875 ± 0.095 h1 (-3 ± 11%), myocardium: 0.641 ± 0.105 h1 (11 ± 25%), kidneys: 1.378 ± 0.266 h1 (14 ± 16%), and liver: 0.685 ± 0.072 h1 (7 ± 9%). Significant sex differences were found for kE in the cerebellum, lungs and kidneys. Effective dose was 4.67 ± 0.18 µSv/MBq for men and 4.55 ± 0.18 µSv/MBq for women. LAFOV PET/CT with [11C]BMP potentially allows for simultaneous assessment of MRP function in multiple human tissues. Mean TRTV of kE in different tissues was in an acceptable range, except for the retina. The radiation dosimetry of [11C]BMP was in the typical range of 11C-tracers. LAFOV PET/CT holds great potential to assess at a whole-body, multi-tissue level molecular targets relevant for drug disposition in humans.

Availability note (English)

Available from: http://dx.doi.org/10.1007/s00259-024-06851-2

Additional details

Identifiers

Publishing Information

Journal Title
European Journal of Nuclear Medicine and Molecular Imaging
Journal Volume
51
Journal Issue
13
Journal Page Range
p. 3900-3911
ISSN
1619-7070
CODEN
EJNMA6